• Institute for Clinical Systems Improvement (ICSI). Lipid management in adults. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2007 Jun. 77 p. [128 references]

Does not apply to this measure

This measure is used to assess the percentage of patients on a lipid-lowering medication who have a fasting lipid panel every 3 to 12 months.

The priority aim addressed by this measure is to improve the percentage of patients on lipid-lowering medication who receive regular follow-up care for lipid disorder.

Dyslipidemia; lipid-lowering medication (bile acid sequestrant [BAS], fibric acids, niacin, statin); fasting lipid panel (total cholesterol, high-density lipoprotein [HDL]-cholesterol, triglycerides, and calculated low-density lipoprotein [LDL]-cholesterol)

Total number of patients who are on lipid-lowering medication whose records are reviewed (see the related "Denominator Inclusions/Exclusions" field in the Complete Summary)

Number of patients on lipid-lowering medication who have a fasting lipid panel (see the related "Numerator Inclusions/Exclusions" field in the Complete Summary)

• A clinical practice guideline or other peer-reviewed synthesis of the clinical evidence

Unspecified

Current routine use

Internal quality improvement

Physician Group Practices/Clinics

Physicians

Group Clinical Practices

Age 20 to 75 years

Either male or female

Unspecified

Unspecified

Unspecified

Unspecified

Unspecified

Unspecified

Living with Illness

Effectiveness

Users of care only

All patients age 20 to 75 who are dyslipidemic and on a lipid-lowering medication

The preferred way to collect these data:

• Patients 20 to 75 years old who are dyslipidemic and on a lipid-lowering medication could be identified. This would include patients with hypercholesterolemia (high low-density lipoprotein [LDL], normal triglycerides and high-density lipoprotein [HDL]), combined hyperlipidemia (high LDL and triglycerides), hypertriglyceridemia and hypercholesterolemia (with isolated low HDL) who are on a lipid-lowering medication.
• Each medical group would select at random 20 patients for measurement each month to determine if a fasting lipid panel has been done in the past 3 to 12 months.

Data on 20 patients are collected monthly and reported quarterly.

Patients associated with provider

Inclusions
Total number of patients who are on lipid-lowering medication* whose records are reviewed

*Patients age 20 to 75 years old who are dyslipidemic on a lipid-lowering medication**, including: bile acid sequestrant (BAS), fibric acids, niacin, statin.

**Refer to Appendix C, "Drug Companion Document - Treatment Options for Dyslipidemia" in the original measure documentation for a complete listing of lipid-lowering medications.

Exclusions
Unspecified

All cases in the denominator are equally eligible to appear in the numerator

Clinical Condition
Therapeutic Intervention

Time window precedes index event

Inclusions
Number of patients on lipid-lowering medication who have a fasting lipid panel*

*Of the patients in the denominator, those who have had a fasting lipid panel in the past 3 to 12 months (measurement of total cholesterol, high-density lipoprotein [HDL]-cholesterol, triglycerides and calculated low-density lipoprotein [LDL]-cholesterol after a 12-hour fasting period).

Exclusions
Unspecified

The measure results are somewhat or substantially under the control of the health care professionals, organizations and/or policymakers to whom the measure applies.

Fixed time period

Administrative data
Medical record

Individual Case

Unspecified

Rate

Better quality is associated with a higher score

Unspecified

Internal time comparison

Unspecified

Percentage of patients on a lipid-lowering medication who have a fasting lipid panel every 3 to 12 months.

Institute for Clinical Systems Improvement

Work Group Members: Tony Woolley, MD (Work Group Leader) (Park Nicollet Health Services) (Internal Medicine); Stephen Kopecky, MD (Mayo Clinic) (Cardiology); Thomas Kottke, MD (HealthPartners Medical Group) (Cardiology); Patrick O'Connor, MD (HealthPartners Medical Group) (Family Medicine); Susan Hanson, RD (Park Nicollet Health Services) (Health Education); William Conroy, MD (Park Nicollet Health Services) (Internal Medicine); Denise Dupras, MD (Mayo Clinic) (Internal Medicine); Phillip Kofron, MD, MPH (Park Nicollet Health Services) (Internal Medicine); Robert Needham, MD (Lakeview Clinic) (Internal Medicine); Sarah Groen, PharmD (HealthPartners Medical Group) (Pharmacy); Amy Murphy, MHHA (Institute for Clinical Systems Improvement) (Implementation Advisor); Ann-Marie Evenson, BS, RHIT (Institute for Clinical Systems Improvement) (Facilitator)

Measure was not adapted from another source.

2003 Jul

2007 Jun

This is the current release of the measure.

This measure updates a previous version: Institute for Clinical Systems Improvement (ICSI). Lipid management in adults. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2006 Jun. 76 p.

• Institute for Clinical Systems Improvement (ICSI). Lipid management in adults. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2007 Jun. 77 p. [128 references]

This NQMC summary was completed by ECRI on April 28, 2004. This NQMC summary was updated by ECRI Institute on June 9, 2005, August 21, 2005, August 4, 2006 and again on October 1, 2007.

This NQMC summary (abstracted Institute for Clinical Systems Improvement [ICSI] Measure) is based on the original measure, which is subject to the measure developer's copyright restrictions.

The abstracted ICSI Measures contained in this Web site may be downloaded by any individual or organization. If the abstracted ICSI Measures are downloaded by an individual, the individual may not distribute copies to third parties.

If the abstracted ICSI Measures are downloaded by an organization, copies may be distributed to the organization's employees but may not be distributed outside of the organization without the prior written consent of the Institute for Clinical Systems Improvement, Inc.

All other copyright rights in the abstracted ICSI Measures are reserved by the Institute for Clinical Systems Improvement, Inc. The Institute for Clinical Systems Improvement, Inc. assumes no liability for any adaptations or revisions or modifications made to the abstracts of the ICSI Measures.